41 completed, 4 unknown, 2 terminated. 13 Phase 3, 10 Phase 1, 7 Phase 2, 7 Phase 4, 6 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 11, Terminated 1, Unknown 1 |
| Phase 1 | 10 | Completed 9, Unknown 1 |
| Phase 2 | 7 | Completed 6, Unknown 1 |
| Phase 4 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Not applicable | 6 | Completed 6 |
Follow lanthanum carbonate: new trials by email Literature Review of lanthanum carbonate trials Research Report on lanthanum carbonate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet - Smallpox | Phase 4 | Completed | SIGA Technologies | 44 | 2022-06-08 | 2026-09-11 |
| To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | Grand Life Science (Liaoning) Co., Ltd. | 48 | 2020-10-21 | 2021-07-28 |
| Different Effects of Non-calcium Phosphate Binders on Serum Calcium Sevelamer Hydrochloride, Lanthanum Carbonate - Chronic Kidney Disease | Phase 4 | Completed | Medical University of Lodz | 34 | 2018-03-01 | 2021-07-27 |
| Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis Lanthanum Carbonate - Secondary Hyperoxaluria, Nephrolithiasis | Phase 3 | Completed | Universitair Ziekenhuis Brussel | 54 | 2017-08-18 | 2026-08-10 |
| A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate ASP1517, Lanthanum carbonate hydrate - Healthy Subjects | Phase 1 | Completed | Astellas Pharma Inc | 18 | 2016-11-01 | 2017-01-25 |
| Healthy Combine Study Nicotinamide, Lanthanum Carbonate, Lanthanum Carbonate Placebo - Healthy | Phase 1 | Completed | Northwestern University | 39 | 2016-02-03 | 2024-02-23 |
| Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet Fosrenol ODT (Lanthanum Carbonate, BAY77-1931), Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) - Clinical Pharmacology | Phase 1 | Completed | Bayer | 20 | 2015-06-10 | 2017-03-21 |
| The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE Nicotinamide, Lanthanum Carbonate, Placebo (for Nicotinamide) - Chronic Kidney Disease | Phase 2 | Completed | The Cleveland Clinic | 205 | 2015-03-01 | 2021-08-02 |
| Phosphate Lowering in CKD Trial Lanthanum carbonate, placebo, Ascorbic Acid - Chronic Kidney Disease, Cardiovascular Disease | Phase 4 | Completed | VA Office of Research and Development | 66 | 2014-09-15 | 2022-08-26 |
| Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Lanthanum carbonate, Calcium Carbonate - Renal Insufficiency, Chronic, Hyperphosphatemia | Phase 4 | Unknown | Osaka University | 60 | 2014-09-01 | 2021-02-25 |
| Fosrenol Post-marketing Surveillance in Japan Lanthanum Carbonate (Fosrenol, BAY77-1931) - Hyperphosphatemia, Kidney Disease | Completed | Bayer | 343 | 2013-10-10 | 2018-02-23 | |
| A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis Lanthanum Carbonate, Calcium Carbonate - Chronic Kidney Disease, Hyperphosphatemia | Phase 2 | Completed | Shire | 63 | 2013-02-15 | 2021-06-10 |
| Fosrenol and Phosphorus Balance - Lanthanum Carbonate lanthanum carbonate - Chronic Kidney Failure, End-stage Renal Disease | Not applicable | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 9 | 2012-03-01 | 2017-05-09 |
| Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study Lanthanum Carbonate, Calcium Carbonate - Hemodialysis, Hyperphosphatemia | Phase 3 | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2309 | 2011-12-24 | 2020-11-30 |
| The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 Lanthanum carbonate, Calcium Carbonate - Other Nonspecific Abnormal Serum Enzyme Levels | Phase 4 | Unknown | Camillians Saint Mary's Hospital Luodong | 30 | 2011-08-01 | 2013-05-03 |
| Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Diet counseling, Phosphorus binder - Chronic Kidney Disease | Phase 3 | Unknown | Salem Veterans Affairs Medical Center | 120 | 2011-06-01 | 2012-06-12 |
| Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease Lanthanum Carbonate, NeutraPhos, Diet Only - Chronic Kidney Disease | Not applicable | Completed | Geoffrey Block | 15 | 2011-04-01 | 2014-02-11 |
| Efficacy of Lanthanum Carbonate in Calciphylaxis lanthanum carbonate, Lanthanum for calciphylaxis - Calciphylaxis | Phase 1 | Completed | University of Wisconsin, Madison | 12 | 2011-02-01 | 2014-05-20 |
| Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD Lanthanum carbonate, Placebo - Chronic Kidney Disease | Phase 2 | Completed | Shire | 35 | 2010-12-06 | 2021-06-09 |
| Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Fosrenol (Lanthanum Carbonate, BAY77-1931) - Hyperphosphatemia | Phase 3 | Completed | Bayer | 123 | 2010-09-01 | 2015-04-03 |
Showing 20 of 47. Sign in to see all of them.
Hyperphosphatemia (21) · Kidney Failure, Chronic (12) · Renal Insufficiency, Chronic (11) · Kidney Diseases (6) · Vascular Calcification (3) · Bone Diseases, Metabolic (2) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Bronchiolitis Obliterans Syndrome (1) · Calciphylaxis (1) · Cardiovascular Diseases (1) · Hyperoxaluria (1) · Hyperparathyroidism, Secondary (1) · Nephrolithiasis (1) · Smallpox (1) · Urolithiasis (1)
Shire (15) · Bayer (10) · University of Illinois at Chicago (2) · Astellas Pharma Inc (1) · Camillians Saint Mary's Hospital Luodong (1) · Denver Nephrologists, P.C. (1) · Endeavor Health (1) · Geoffrey Block (1) · Grand Life Science (Liaoning) Co., Ltd. (1) · Ineos Healthcare Limited (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Massachusetts General Hospital (1) · Medical University of Lodz (1) · Myles Wolf (1) · Northwestern University (1)
United States (21) · Japan (13) · Germany (6) · Poland (3) · Belgium (2) · France (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Czechia (1)
Alan H Lau, Pharm.D. (2) · Geoffrey A Block, MD (2) · Myles Wolf, MD, MMSc (2) · Anna J Jovanovich, MD (1) · Christian Tielemans, MD, PhD (1) · Csaba P. Kovesdy, M.D. (1) · Dennis Hruby, PhD (1) · Harald Jueppner, MD (1) · Jennifer J Gassman, Ph.D. (1) · Joel D. Kopple, M.D. (1) · John W. Kusek, PhD (1) · Linda F Fried, MD (1)
PMID 40576086, PMID 18579668, PMID 19056618, PMID 20631407, PMID 20921291, PMID 21354682, PMID 21426511, PMID 22657252, PMID 23471131, PMID 24197066, PMID 24307220, PMID 24885942, PMID 25069799, PMID 25079863, PMID 27357090, PMID 27928636, PMID 29989014, PMID 31085679, PMID 32345747, PMID 34003226, PMID 34754193, PMID 35236302, PMID 38570905, PMID 38781013, PMID 41033875
2004 (1), 2008 (1), 2009 (1), R01DK076116 (1), U01DK099877 (1)